肉毒毒素注射治疗磨牙症的临床表现：回顾性研究

IF 2.4 4区医学 Q2 PHARMACOLOGY & PHARMACY

Toxicon Pub Date : 2025-08-04 DOI:10.1016/j.toxicon.2025.108516

Imen Mehri Turki

{"title":"肉毒毒素注射治疗磨牙症的临床表现：回顾性研究","authors":"Imen Mehri Turki","doi":"10.1016/j.toxicon.2025.108516","DOIUrl":null,"url":null,"abstract":"<div><h3>Context</h3><div>The effectiveness of botulinum toxin (BTX) in treating bruxism is recognised and well-established. However, it is often recommended in cases of severe bruxism.</div></div><div><h3>Objectives</h3><div>This study aims to highlight the performance of trigger points (TrPs) released with BTX injections at an early stage of bruxism while providing an overview of its analgesic effect.</div></div><div><h3>Methods</h3><div>67 patients who suffered from bruxism between 2009 and 2015 and who recovered completely after injection sessions. Patients were divided into two groups based on bruxism duration. The main outcomes were pain relief, injection sessions, required doses, and recovery duration between two consecutive sessions. The treatment was stopped when bruxism disappeared.</div></div><div><h3>Results</h3><div>Out of all the patients who experienced long-standing symptoms, 70,3 % were given high doses of toxin, while only 16,67 % of patients with recent bruxism received similar doses. Long-standing bruxism required more injection sessions than recent bruxism where the time to recurrence between sessions was longer. The follow-up varied from 16 to 55 months.</div></div><div><h3>Conclusion</h3><div>Our study highlights promising and reliable results in treating bruxism and myofascial pain using botulinum toxin, particularly in trigger points, where the earlier it is started, the lower the doses and the better the effect in the long term.</div></div>","PeriodicalId":23289,"journal":{"name":"Toxicon","volume":"266 ","pages":"Article 108516"},"PeriodicalIF":2.4000,"publicationDate":"2025-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinical performance of Botulinum Toxin injections in the treatment of bruxism: A retrospective study\",\"authors\":\"Imen Mehri Turki\",\"doi\":\"10.1016/j.toxicon.2025.108516\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Context</h3><div>The effectiveness of botulinum toxin (BTX) in treating bruxism is recognised and well-established. However, it is often recommended in cases of severe bruxism.</div></div><div><h3>Objectives</h3><div>This study aims to highlight the performance of trigger points (TrPs) released with BTX injections at an early stage of bruxism while providing an overview of its analgesic effect.</div></div><div><h3>Methods</h3><div>67 patients who suffered from bruxism between 2009 and 2015 and who recovered completely after injection sessions. Patients were divided into two groups based on bruxism duration. The main outcomes were pain relief, injection sessions, required doses, and recovery duration between two consecutive sessions. The treatment was stopped when bruxism disappeared.</div></div><div><h3>Results</h3><div>Out of all the patients who experienced long-standing symptoms, 70,3 % were given high doses of toxin, while only 16,67 % of patients with recent bruxism received similar doses. Long-standing bruxism required more injection sessions than recent bruxism where the time to recurrence between sessions was longer. The follow-up varied from 16 to 55 months.</div></div><div><h3>Conclusion</h3><div>Our study highlights promising and reliable results in treating bruxism and myofascial pain using botulinum toxin, particularly in trigger points, where the earlier it is started, the lower the doses and the better the effect in the long term.</div></div>\",\"PeriodicalId\":23289,\"journal\":{\"name\":\"Toxicon\",\"volume\":\"266 \",\"pages\":\"Article 108516\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2025-08-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Toxicon\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0041010125002910\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Toxicon","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0041010125002910","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

摘要

背景肉毒毒素（BTX）治疗磨牙症的有效性是公认和完善的。然而，在严重磨牙的情况下，通常建议使用这种方法。目的本研究旨在强调BTX注射在磨牙症早期释放触发点（TrPs）的性能，同时概述其镇痛效果。方法选取2009 ~ 2015年67例磨牙患者，经注射后完全康复。根据磨牙持续时间将患者分为两组。主要结果为疼痛缓解、注射次数、所需剂量和两次连续注射之间的恢复时间。磨牙消失后停止治疗。结果在所有有长期症状的患者中，703%的患者给予了高剂量的毒素，而在近期磨牙患者中，只有16.67%的患者给予了类似的剂量。长期磨牙比近期磨牙需要更多的注射疗程，而近期磨牙的复发时间更长。随访时间从16到55个月不等。结论本研究强调了肉毒毒素治疗磨牙和肌筋膜疼痛的前景和可靠的结果，特别是在触发点，越早开始使用，剂量越低，长期效果越好。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Clinical performance of Botulinum Toxin injections in the treatment of bruxism: A retrospective study

Context

The effectiveness of botulinum toxin (BTX) in treating bruxism is recognised and well-established. However, it is often recommended in cases of severe bruxism.

Objectives

This study aims to highlight the performance of trigger points (TrPs) released with BTX injections at an early stage of bruxism while providing an overview of its analgesic effect.

Methods

67 patients who suffered from bruxism between 2009 and 2015 and who recovered completely after injection sessions. Patients were divided into two groups based on bruxism duration. The main outcomes were pain relief, injection sessions, required doses, and recovery duration between two consecutive sessions. The treatment was stopped when bruxism disappeared.

Results

Out of all the patients who experienced long-standing symptoms, 70,3 % were given high doses of toxin, while only 16,67 % of patients with recent bruxism received similar doses. Long-standing bruxism required more injection sessions than recent bruxism where the time to recurrence between sessions was longer. The follow-up varied from 16 to 55 months.

Conclusion

Our study highlights promising and reliable results in treating bruxism and myofascial pain using botulinum toxin, particularly in trigger points, where the earlier it is started, the lower the doses and the better the effect in the long term.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Toxicon 医学-毒理学

CiteScore

4.80

自引率

10.70%

发文量

358

审稿时长

68 days

期刊介绍： Toxicon has an open access mirror Toxicon: X, sharing the same aims and scope, editorial team, submission system and rigorous peer review. An introductory offer Toxicon: X - full waiver of the Open Access fee. Toxicon''s "aims and scope" are to publish: -articles containing the results of original research on problems related to toxins derived from animals, plants and microorganisms -papers on novel findings related to the chemical, pharmacological, toxicological, and immunological properties of natural toxins -molecular biological studies of toxins and other genes from poisonous and venomous organisms that advance understanding of the role or function of toxins -clinical observations on poisoning and envenoming where a new therapeutic principle has been proposed or a decidedly superior clinical result has been obtained. -material on the use of toxins as tools in studying biological processes and material on subjects related to venom and antivenom problems. -articles on the translational application of toxins, for example as drugs and insecticides -epidemiological studies on envenoming or poisoning, so long as they highlight a previously unrecognised medical problem or provide insight into the prevention or medical treatment of envenoming or poisoning. Retrospective surveys of hospital records, especially those lacking species identification, will not be considered for publication. Properly designed prospective community-based surveys are strongly encouraged. -articles describing well-known activities of venoms, such as antibacterial, anticancer, and analgesic activities of arachnid venoms, without any attempt to define the mechanism of action or purify the active component, will not be considered for publication in Toxicon. -review articles on problems related to toxinology. To encourage the exchange of ideas, sections of the journal may be devoted to Short Communications, Letters to the Editor and activities of the affiliated societies.